News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeoPharm (NEOL) Announces Japanese Licensing Agreement For IL13-PE38QQR With Nippon Kayaku


10/19/2005 5:11:34 PM

NeoPharm, Inc. (Nasdaq:NEOL) today announced that Nippon Kayaku Co., Ltd. has signed an exclusive license agreement with NeoPharm for the Japanese development rights for IL13-PE38QQR, generically known as cintredekin besudotox (sin" tre dek' in be soo' doe tox), which is NeoPharm's lead drug candidate for the treatment of glioblastoma multiforme (GBM).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES